[Gender difference in clinical practice for cancer patients].
Solid tumors are generally more detected in male than female patients, except for sexual organs. However, females are dominant in biliary tract cancer, especially gallbladder cancer. Gender difference is not recognized in hematological malignancies. Selection of therapeutic agents is not influenced by gender, but nausea and vomiting as side effects of anti-cancer agents are more common in young females. Therefore, sufficient anti-emetic agents should be used especially at the first cycle of chemotherapy with highly emetic drugs such as cisplatin in order to prevent anticipatory nausea and vomiting. Furthermore, neutropenia due to the combination regimen of platinum plus gemcitabine or the monotherapy of gemcitabine or amrubicin is reported to be more frequent in females than males.